Arrowhead Pharmaceuticals Inc (ARWR)

Return on equity (ROE)

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Net income (ttm) US$ in thousands -1,631 -148,417 -143,969 -639,714 -599,493 -538,636 -470,789 -296,814 -205,275 -181,107 -150,207 -154,516 -176,063 -153,926 -111,804 -182,988 -140,848 -125,907 -109,594 -102,612
Total stockholders’ equity US$ in thousands 466,052 519,806 683,321 52,589 185,444 330,547 483,794 160,407 271,343 364,830 446,772 377,039 105,960 453,927 452,266 372,560 408,822 436,890 445,549 454,472
ROE -0.35% -28.55% -21.07% -1,216.44% -323.27% -162.95% -97.31% -185.04% -75.65% -49.64% -33.62% -40.98% -166.16% -33.91% -24.72% -49.12% -34.45% -28.82% -24.60% -22.58%

September 30, 2025 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-1,631K ÷ $466,052K
= -0.35%